Modulation of tetraspanin function
View Patent ↗Tetraspanins have been found to dimerise. Methods for inhibiting or promoting the dimerisation of tetraspanins are provided, which may involve protein engineering of the tetraspanins themselves, or may rely on other molecules.
1. A method for modulating the ability of a tetraspanin protein to form a dimer with the wild-type tetraspanin, comprising the step of mutating at least one of the amino acids corresponding to human CD81 (SEQ ID NO:1) residues 114, 119, 123, 125, 126, 129, 142, 146, 149, 150, 153, 154, 197, 198, 199 and 200; wherein said mutated tetraspanin protein has a decreased ability to form a dimer with the wild-type tetraspanin.
2. The method of claim 1 , wherein in the step of mutating at least one of the amino acids a non-polar residue is replaced by a polar residue.
3. The method of claim 1 , wherein in the step of mutating at least one of the amino acids a non-polar residue is replaced by another non-polar residue.
4. The method of claim 1 , wherein the tetraspanin is selected from the group consisting of CD9, TSPAN2, CD53, CD82, CD63, TALLA-1, and NET4.
5. The method of claim 4 , wherein the tetraspanin is CD82.
6. The method of claim 4 , wherein the tetraspanin is CD63.
7. A method for modulating the ability of a tetraspanin CD81 protein to form a dimer with a wild-type tetraspanin, comprising the step of mutating at least one of the amino acids corresponding to human CD81 (SEQ ID NO:1) residues 114, 119, 123, 125, 126, 129, 142, 146, 149, 150, 153, 154, 197, 198, 199 and 200; wherein said tetraspanin CD81 protein has a decreased ability to form a dimer with the wild-type tetraspanin.
8. A mutant tetraspanin protein which, compared with the wild-type protein, has a decreased ability to form a dimer with the wild-type protein.
9. The mutant tetraspanin of claim 8 , wherein the mutant has a non-wild-type amino acid at one or more residues corresponding to human CD81 (SEQ ID NO:1) residues 114, 119, 123, 125, 126, 129, 142, 146, 149, 150, 153, 154, 197, 198, 199 and 200.
10. The mutant tetraspanin of claim 9 , wherein the tetraspanin is selected from the group consisting of CD9, TSPAN2, CD53, CD82, CD63, TALLA-1, and NET4.
11. The method of claim 10 , wherein the tetraspanin is CD82.
12. The method of claim 10 , wherein the tetraspanin is CD63.
13. The mutant tetraspanin of claim 9 , wherein the tetraspanin is CD81.
14. A tetraspanin dimer, wherein one or both of the monomers is a mutant tetraspanin according to any one of claims 8 to 13 .